Investigators evaluated the relationship between atopic dermatitis and frequency of severity markers in patients hospitalized with COVID-19.
Drugs in the Pipeline
Findings showed that the trial did not meet statistical significance on the primary endpoint.
The EUA was issued based on 4 randomized controlled clinical trials that evaluated the efficacy and safety of Actemra in more than 5500 hospitalized patients with COVID-19.
Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.